New Implant and Needle-Free Solution, CardioID, Uses AI and ML to Surpass Accuracy of Conventional Heart Monitoring

November 12, 2024 12:00 PM Eastern Standard Time

PALO ALTO, Calif.–(BUSINESS WIRE)–NEC X, the Silicon Valley venture studio backed by NEC’s portfolio of advanced technologies and global businesses, today announced a new investment in General Prognostics Inc. (GPx), a fast-growing MedTech startup revolutionizing chronic disease monitoring and management.

“This collaboration will not only help us improve the performance of our technology, but also accelerate our growth and ability to help patients with chronic diseases worldwide.”Post this

The investment coincides with GPx joining the Elev X! Boost program, an individually tailored venture program for ambitious startups that are ready to scale. The program offers a unique blend of capital, strategic partnerships, and integrations with NEC X’s expansive tech ecosystem to propel startups to global success.

Through Elev X! Boost, GPx will refine the accuracy of its debut product, CardioID, the world’s first implant and needle-free remote blood monitoring solution for heart failure patients, while growing revenue, expanding into new markets and securing additional funding. The system, developed by GPx, extracts biomarkers from wearable devices, such as heart rate, heart rate variability, step count, and voice data, and employs machine learning to develop predictive models that surpass the accuracy of traditional implant-based monitoring solutions.

“GPx’s innovative approach to heart monitoring and chronic disease management is a perfect fit for the NEC Group’s vision of leveraging advanced technology to improve quality of life,” said Shintaro Matsumoto, President and CEO of NEC X. “By joining forces with GPx, we aim to enhance their predictive algorithms and capabilities. Together, we can transform the healthcare industry.”

GPx aims to improve the lives of individuals with chronic diseases by providing personalized, predictive monitoring solutions. Conventional heart failure monitoring typically relies on invasive implants, limiting its use to patients with severe conditions. CardioID addresses this gap by offering non-invasive, real-time monitoring without the need for surgery or frequent blood tests, significantly expanding access to continuous care for the majority of heart failure patients who are unable to receive implant-based monitoring.

“NEC X’s investment and strategic partnership are invaluable as we work to expand our mission of providing personalized healthcare solutions to millions of patients,” said Sean Matsuoka, Co-Founder of GPx. “This collaboration will not only help us improve the performance of our technology, but also accelerate our growth and ability to help patients with chronic diseases worldwide.”

GPx’s leadership team, composed of graduates from MIT and Harvard, offers deep expertise across engineering, legal, product management, and sales in healthcare and medical devices. Its co-founders Sean Matsuoka and Javier Echenique have held leadership roles at Caresyntax, M3, McKinsey & Company, Sony Corporation, Jana Care, Medtronic, and Volcano. Additionally, the startup’s founding advisor Sidhant Jena co-founded and served as CEO of Jana Care and held R&D leadership roles at Medtronic.

The investment in GPx is part of NEC X’s broader strategy to support healthcare innovation. By fostering partnerships with startups like GPx, NEC X aims to address critical challenges in healthcare, such as improving access to monitoring for chronic disease patients and reducing the burden on healthcare systems. The investment will support GPx’s growth and development as they prepare to scale their operations and bring CardioID to market.

About General Prognostics Inc.

General Prognostics (GPx) is revolutionizing remote chronic disease management with the world’s first bloodless blood tests. Headquartered in Boston, MA, GPx is dedicated to transforming the standard of care of chronic diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.

For more information about GPx and their innovative healthcare solutions, visit https://www.gpx.ai.

About NEC X

NEC X is an innovation powerhouse and curator of disruptive startups backed by the global technology leadership of NEC. Leveraging 125 years of IT and network technologies expertise, NEC X’s startup-focused approach transforms visionary ideas into commercial successes that revolutionize how we work and live. Since its inception in 2018, NEC X has helped launch and grow more than 100 startups.

Their Silicon Valley programs – Elev X! Ignite and Elev X! Boost – equip early-stage startup founders with the tools to fast-track their tech development and adoption. Elev X! fuels startup success from inception to launch, connecting innovators with NEC’s 45,000 patents; global network of partners, mentors and advisors; reach into 55+ international markets; and $8 billion R&D ecosystem.

For more information, visit https://nec-x.com and https://www.elev-x.com.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.

For more information, visit NEC at https://www.nec.com.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2024 NEC Corporation.

Contacts

Media Contact
Robert Brownlie
Bob Gold & Associates
310-320-2010
necx@bobgoldpr.com

(c)2024 Business Wire, Inc., All rights reserved.